2 citations
,
July 2024 in “Journal of Cosmetic Dermatology” The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.
2 citations
,
March 2025 in “JAMA Dermatology” This review evaluates the quality of alopecia areata-specific patient-reported outcome measures and suggests that more high-quality validation studies are needed to enhance their reliability and validity.
1 citations
,
January 2025 in “JEADV Clinical Practice” This study reported that the AAPPO tool effectively distinguishes between patients with alopecia areata based on scalp hair loss severity, whereas the EQ‐5D‐5L may underestimate the specific disease burden, particularly in psychological and social aspects.
June 2026 in “British Journal of Dermatology” In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.
May 2011 in “Value in Health” This review assessed patient-reported outcome measures for alopecia treatments but found that none met current FDA guidelines; however, some could potentially be adapted for more comprehensive use.